Company Profile

Cartesian Therapeutics Inc
Profile last edited on: 12/1/2023      CAGE: 7NM42      UEI: PXGLS86SY6B1

Business Identifier: Novel cellular immunotherapies to cure cancer
Year Founded
First Award
Latest Award
Program Status
Active (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

704 Quince Orchard Road
Gaithersburg, MD 20878
   (301) 348-8698
Location: Single
Congr. District: 06
County: Montgomery

Public Profile

Cartesian Therapeutics is abiotechnology company structured around immunotherapy. Originally developed by NIH researchers, the firm's proprietary technology, has the potential to greatly broaden the use of Chimeric Antigen Receptor (CAR) cells for patients with multiple myeloma and other diseases. Although treatment has improved significantly in the past two decades, nearly all patients eventually relapse, and the disease remains incurable. Chimeric antigen receptor (CAR) therapies are the primary focus of Cartesian personnel; and the firm's lead product: Descartes-08,

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Carsten Brunn -- President and CEO

  Kristen Baldwin -- Chief People Officer

  Matthew Bartholomae -- General Counsel Secretary

  Albina Benson -- Senior Director Manufacturing

  Blaine Davis -- Chief Financial Officer

  Emily English -- Vp Quality Assurance

  Chris Jewell -- Chief Scientific Officer

  Murat Kalayoglu -- President and CEO

  Metin Kurtoglu -- Chief Operating Officer

  Milos Miljkovic -- Chief Medical Officer

  Charles Andrew Stewart -- VP Research

  Yi Zhang -- Senior Director Technology